- Provider
- CoreAge Rx
- Advertised starting price
- $129 per month; confirm selected plan
- Comparison category
- Compounded preparation, not branded Zepbound
- Price basis
- Publisher-supplied correction; confirm selected plan
A separate product from Zepbound
This program is described as compounded tirzepatide. It should not be labeled Zepbound, an approved generic or a trial-tested equivalent merely because the named active is tirzepatide.[source]
Confirm the complete preparation and dispensing pharmacy. A medication access review can describe the offer, but it cannot determine clinical eligibility or the appropriateness of compounding for an individual.
Check the selected billing arrangement
The publisher-corrected starting offer is $129 per month with a same-price-at-every-dose statement. Request the actual charge, plan length and included services before comparing it with a starting-dose price from another provider.[source]
The surrounding catalog includes multi-month commitments and a consultation-fee exception when treatment is declined. Ask which terms apply to the intended purchase.[source]
The head-to-head result belongs to its studied product
SURMOUNT-5 found a larger average weight reduction with its tirzepatide regimen than its semaglutide regimen. That study did not evaluate CoreAge Rx or compounded tirzepatide. Applying its percentages to this program would imply evidence we have not verified.[source]
The prescription needs an understandable support plan
Ask how medication questions, side effects and changes are reviewed. Identify the clinician responsible for care and the pharmacy responsible for dispensing. We did not measure response times or verify patient outcomes.
FDA’s discussion of unapproved GLP-1 products is relevant to the evidence and preparation questions. The provider’s commercial position does not replace that regulatory context.[source]
Compare like with like, then compare access routes
Mochi offers another compounded tirzepatide route with dose-dependent pricing. Zepbound through Ro, Hers or LillyDirect belongs in a separately identified approved-product category. Compare the actual formulation, complete cost and ongoing care rather than ingredient names alone.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- CoreAge Rx: current advertised treatments and pricesStandard GLP-1 prices use the publisher-supplied correction: semaglutide $79/month from; tirzepatide $129/month from. Other original service details retain their October 8 check date. · Checked October 8, 2026
- CoreAge Rx Help Center: current product catalogProvider formulation and consultation information · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026